La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Harvard Bioscience Crescita futura

Future criteri di controllo 0/6

Harvard Bioscience prevede che gli utili e i ricavi cresceranno rispettivamente di 83% e 7.8% all'anno. Si prevede che l'EPS crescerà di 84.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -0.2% in 3 anni.

Informazioni chiave

83.0%

Tasso di crescita degli utili

84.5%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili	17.9%
Tasso di crescita dei ricavi	7.8%
Rendimento futuro del capitale proprio	-0.2%
Copertura analitica	Low
Ultimo aggiornamento	09 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Dec 11

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:HBIO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	123	2	8	12	1
12/31/2025	107	-3	4	7	2
12/31/2024	98	-11	-2	1	2
6/30/2024	101	-11	6	9	N/A
3/31/2024	107	-9	11	14	N/A
12/31/2023	112	-3	12	14	N/A
9/30/2023	113	-3	11	12	N/A
6/30/2023	114	-5	7	9	N/A
3/31/2023	115	-2	4	5	N/A
12/31/2022	113	-10	0	1	N/A
9/30/2022	118	-7	-3	-1	N/A
6/30/2022	121	-4	-4	-3	N/A
3/31/2022	121	-6	-3	-2	N/A
12/31/2021	119	0	0	1	N/A
9/30/2021	117	-2	2	4	N/A
6/30/2021	111	-3	5	6	N/A
3/31/2021	105	-4	6	7	N/A
12/31/2020	102	-8	8	9	N/A
9/30/2020	102	-7	8	9	N/A
6/30/2020	105	-8	9	11	N/A
3/31/2020	112	-7	8	9	N/A
12/31/2019	116	-5	7	8	N/A
9/30/2019	119	-2	8	8	N/A
6/30/2019	120	0	3	4	N/A
3/31/2019	122	-1	4	4	N/A
12/31/2018	121	-4	2	3	N/A
9/30/2018	109	-8	-2	-1	N/A
6/30/2018	99	-8	2	3	N/A
3/31/2018	86	-7	N/A	2	N/A
12/31/2017	77	-2	N/A	1	N/A
9/30/2017	82	-3	N/A	4	N/A
6/30/2017	88	-4	N/A	5	N/A
3/31/2017	96	-4	N/A	5	N/A
12/31/2016	105	-4	N/A	5	N/A
9/30/2016	106	-20	N/A	5	N/A
6/30/2016	107	-19	N/A	2	N/A
3/31/2016	110	-18	N/A	0	N/A
12/31/2015	109	-19	N/A	1	N/A
9/30/2015	111	-2	N/A	0	N/A
6/30/2015	110	0	N/A	1	N/A
3/31/2015	109	0	N/A	3	N/A
12/31/2014	109	2	N/A	4	N/A
9/30/2014	106	2	N/A	4	N/A
6/30/2014	106	1	N/A	5	N/A
3/31/2014	105	1	N/A	5	N/A
12/31/2013	105	1	N/A	4	N/A
9/30/2013	106	4	N/A	4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che HBIO rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di HBIO ( 7.8% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HBIO ( 7.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che HBIO non sarà più redditizia tra 3 anni.

Harvard Bioscience Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Forecast breakeven date moved forward to 2023

Recent updates

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought US$75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought US$83k worth of stock

President recently bought US$128k worth of stock

Forecast breakeven date pushed back to 2023

Price target decreased to US$8.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought US$111k worth of stock

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

President recently bought US$147k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Full year 2021 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

President recently sold US$386k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Price target increased to US$9.67

Harvard Bioscience, Inc. Files A Motion to Vacate the Suffolk Superior Court’S Order Allowing Plaintiff’S Motion for Sanctions